RBC Capital analyst Luca Issi raised the firm’s price target on Arrowhead (ARWR) to $52 from $45 and keeps an Outperform rating on the shares. The FDA approved plozasiran, Redemplo, for familial chylomicronemia syndrome, which is a key milestone for the organization as it marks the very first FDA approved drug for the company, the analyst tells investors in a research note. While approval was largely anticipated, RBC is positive on Arrowhead’s solid execution and its ability to successfully transition to a commercial organization, the firm added.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead price target raised to $70 from $45 at Piper Sandler
- Arrowhead Pharmaceuticals: Strong Market Position and Growth Potential with REDEMPLO’s FDA Approval
- Arrowhead Pharmaceuticals: Hold Rating Amid Market Challenges and Future Opportunities
- Arrowhead Pharmaceuticals’ REDEMPLO Approved by FDA
- Arrowhead trading resumes